CASµÇ¼ºÅ | ÖÐÎÄÃû | Ó¢ÎÄÃû | ·Ö×ӽṹʽ | ·Ö×Óʽ | ÏêÇé | ¹©Ó¦ÉÌ |
81493-98-3 | ÀÒ°±Ëἤø | H-ARG-ARG-LEU-ILE-GLU-ASP-ASN-GLU-Tyr-Thr-ALA-ARG-GLY-OH; ARG-ARG-LEU-ILE-GLU-ASP-ASN-GLU-Tyr-Thr-ALA-ARG-GLY; H-ARG-ARG-LEU-ILE-GLU-ASP-ASN-GLU-Tyr-Thr-ALA-ARG-GLY-OH; TYROSINE KINASE SUBSTRATE; RRLIEDNEYTARG; PP60(V-SRC) AUTOPHOSPHORYLATION SITE; PP60V-SRC FRAGMENT; arg-arg-leu-ile-glu-asp-asn-glu-tyr-*thr-ala-arg-; TYROSINE KINASE SUBSTRATE SYNTHETIC >96% | ![]() | C66H109N23O23 | ÏêÇé | ¹©Ó¦ÉÌ |
89991-90-2 | ÉÏÆ¤Éú³¤Òò×ÓÆ¬¶Ï | (CYS(ACM)20,31)-EGF (20-31); (CYS(ACM)20,31)-EGF (20-31); (CYS(ACM)20,31)-EPIDERMAL GROWTH FACTOR (20-31); [CYS(ACM)20,31]-EPIDERMAL GROWTH FACTOR FRAGMENT 20-31; CYS(ACM)-MET-HIS-ILE-GLU-SER-LEU-ASP-SER-Tyr-Thr-CYS(ACM); CYS[S-ACETAMIDOMETHYL]-MET-HIS-ILE-GLU-SER-LEU-ASP-SER-Tyr-Thr-CYS[ACM]; H-CYS(ACM)-MET-HIS-ILE-GLU-SER-LEU-ASP-SER-Tyr-Thr-CYS(ACM)-OH; (cys(acm)20,31)-epidermal growth factor fragment; (CYS(ACM)20,31)-EPIDERMAL GROWTH FACTOR FRAGMENT 20 | ![]() | C63H97N16O22S3* | ÏêÇé | ¹©Ó¦ÉÌ |
125093-93-8 | VIP ANTAGONIST | H-LYS-PRO-ARG-ARG-PRO-Tyr-Thr-ASP-ASN-Tyr-Thr-ARG-LEU-ARG-LYS-GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ASN-SE; H-LYS-PRO-ARG-ARG-PRO-Tyr-Thr-ASP-ASN-Tyr-Thr-ARG-LEU-ARG-LYS-GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ASN-SER-ILE-LEU-ASN-NH2; KPRRPYTDNYTRLRKQMAVKKYLNSILN-NH2; VASOACTIVE INTESTINAL PEPTIDE ANTAGONIST; VIP ANTAGONIST; (lys1,pro2,5,arg3,4,tyr6)-vasoactive*intestinal P; (LYS1 PRO2 5 ARG3 4 TYR6)-VASOACTIVE &; (VIP-neurotensin) hybrid antagonist; H-Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 | ![]() | C154H257N49O40S | ÏêÇé | ¹©Ó¦ÉÌ |